Trials / Active Not Recruiting
Active Not RecruitingNCT05556096
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 261 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | ALXN1720 | Combination product consisting of syringe prefilled with ALXN1720. |
| COMBINATION_PRODUCT | Placebo | Combination product consisting of syringe prefilled with placebo. |
Timeline
- Start date
- 2022-11-21
- Primary completion
- 2025-05-27
- Completion
- 2027-08-31
- First posted
- 2022-09-27
- Last updated
- 2026-01-23
Locations
132 sites across 22 countries: United States, Argentina, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Portugal, Serbia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05556096. Inclusion in this directory is not an endorsement.